New combo therapy targets Hard-to-Treat lymphoma in early trial

NCT ID NCT06660563

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times

Summary

This early-stage study tests a new drug combination (JNJ-80948543 plus JNJ-75348780) in 19 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to at least two prior treatments. The main goals are to find the safest dose and check for side effects. This is not a cure, but aims to better control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA NON-HODGKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Concord Hospital

    Concord, 2139, Australia

  • Hosp Univ Vall D Hebron

    Barcelona, 08035, Spain

  • Hosp. Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hosp. Gral. Univ. Gregorio Maranon

    Madrid, 28007, Spain

  • Hosp. Univ. 12 de Octubre

    Madrid, 28041, Spain

  • Inst. Cat. Doncologia-H Duran I Reynals

    L'Hospitalet de Llobregat, 08908, Spain

  • Macquarie University Hospital

    North Ryde, 2109, Australia

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • St Vincents Hospital Melbourne

    Fitzroy, 3065, Australia

  • University Hospitals Of Leicester Nhs Trust

    Leicester, Le1 5ww, United Kingdom

Conditions

Explore the condition pages connected to this study.